

List of Review Article 2016-2017

2017

1. [Lin L, Wu M, Zhao J. The initiation and effects of plasma contact activation: an overview. Int. J. Hematol 2017; 105:235-43.](#)
2. [Jahanban-Esfahlan R, Seidi K, Zarghami N. Tumor vascular infarction: prospects and challenges. Int. J. Hematol 2017; 105:244-56.](#)
3. [Atilla E, Atilla PA, Demirer T. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now? Int. J. Hematol 2017; 105:257-64.](#)
4. [Nomura S. Extracellular vesicles and blood diseases. Int. J. Hematol 2017; 105:392-405.](#)
5. [Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein–Barr virus infection. Int. J. Hematol 2017; 105:405-18.](#)
6. [Sun Z, Lan X, Li S, Zhao H, Tang Z, Xi Y. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis. Int. J. Hematol 2017; online published on June 9, 10.1007/s12185-017-2271-8](#)

2016

1. [Ogawa Y, Ogura M, Tobinai K, Ando K, Suzuki T, Watanabe T, et al. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Int. J. Hematol 2016; 103:25-33.](#)
2. [Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int. J. Hematol. 2016; 103: 253-61.](#)

3. [Nagai S, Ozawa K. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US. Int. J. Hematol. 2016; 104:73-84.](#)
4. [Maeda T. Regulation of hematopoietic development by ZBTB transcription factors. Int. J. Hematol. 2016; 104: 310-23.](#)
5. [Yasunaga S, Ohno Y, Shirasu N, Zhang B, Suzuki-Takedachi K, Ohtsubo M. Role of Geminin in cell fate determination of hematopoietic stem cells \(HSCs\). Int. J. Hematol. 2016; 104: 324-9.](#)
6. [Jiang Y, Chen Y, Huang R, Chen G. Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis. Int. J. Hematol. 2016; 104: 413-9.](#)
7. [Mesa RA, Komrokji RS, Verstovsek S. Ruxolitinib dose management as a key to long-term treatment success. Int. J. Hematol. 2016; 104: 420-9.](#)
8. [Feng Y, Li X, Xiao J, Li W, Liu J, Zeng X, et al. ADAMTS13: more than a regulator of thrombosis. Int. J. Hematol. 2016; 104: 534-39.](#)